The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK. | ...

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project ...

Eli Lilly is partnering on Team USA’s push to help Olympic and Paralympic athletes hurdle the challenges of recovering from ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) will push out its February vaccine confab to an undetermined date next month, Bloomberg reported Thursday, citing an unnamed person close ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...